Sequoia Capital Israel

Danatlas is a pharmaceutical company that develops drugs designed for oncology treatment. It also provides drug research and development in the fields of cancer, inflammation, blood, and metabolic diseases.

Normunity is a biotechnology company that develops precision immuno‑oncology medicines, termed immune normalizers, designed to restore the body’s natural immune response against cancer. Leveraging a partnership with Dr. Lieping Chen’s laboratory at Yale School of Medicine, the company focuses on newly discovered mechanisms of immune disruption, such as the exclusion of T‑cells from immune‑sensitive tumors and other barriers to normal immune function. Its pipeline includes programs targeting these mechanisms to enable clinicians to treat cancer by reactivating the patient’s own immunity. Normunity operates from offices in Boston, Massachusetts, and West Haven, Connecticut.

Full-Life Technologies specializes in developing and commercializing radiopharmaceuticals for cancer therapy. It offers research and development, production, and distribution services within the radiotherapy sector, aiming to enhance patient outcomes through innovative nuclear medicine solutions.

Wuhan Neurophth Biotechnology Co., Ltd. is a pioneering ophthalmology gene drug research and development company based in Wuhan, China, established in 2008. It focuses on gene therapies for ocular genetic diseases, with a particular emphasis on Leber hereditary optic neuropathy (LHON), a condition caused by genetic mutations. Neurophth has made significant advancements in the field, completing the world's first clinical study of gene therapy for LHON in 2011, which involved nine patients and has since observed their progress over seven years. The company aims to develop effective treatments for various ophthalmic disorders, including degenerative optic nerve injuries and vascular retinopathy, thereby providing physicians with innovative therapeutic options for patients suffering from these conditions.

Danatlas is a pharmaceutical company that develops drugs designed for oncology treatment. It also provides drug research and development in the fields of cancer, inflammation, blood, and metabolic diseases.

MoleculeMind is an AI-driven protein design platform focused on revolutionizing protein discovery, optimization, and design. The company utilizes advanced AI algorithms to enhance the drug development process and has applications across various sectors, including industrial production, agriculture, material design, and environmental improvement. MoleculeMind offers an integrated biological computing platform that enables the prediction and design of peptides, antibodies, enzymes, and small proteins, facilitating industrial-scale protein optimization and design for diverse research and application needs.

PhaBuilder is a technology-driven company established in February 2021 by Professor Guoqiang Chen, specializing in synthetic biology with a focus on the engineering application of halophilic microbes. The company employs advanced techniques in Next Generation Industrial Biotechnology to create high-value products such as biodegradable polyhydroxyalkanoates (PHA), ectoine, and cadaverine, targeting multiple sectors, including materials and pharmaceuticals. PhaBuilder is currently constructing two PHA production facilities in China and aims to establish 3-5 large-scale production sites within five years. The company utilizes an interdisciplinary approach that combines biology, engineering, and information technology to transform genetic programs, thereby offering sustainable solutions across diverse fields. With significant backing from notable investors, PhaBuilder is dedicated to integrating synthetic biotechnology into everyday life and advancing intelligent biological manufacturing, with the overarching goal of fostering a greener future through microbial innovation.

Rhegen is engaged in the research and development of mRNA medicine and gene therapy, focusing on synthetic biology technologies to create innovative mRNA drugs and vaccines. The company specializes in platform technologies essential for nucleic acid therapeutics, including mRNA design, synthesis, and non-carrier delivery methods. Rhegen applies these advancements to drug research and development, targeting various clinical indications such as functional protein defects, cancer, and infectious diseases. With a commitment to enhancing drug synthesis and developing novel drug targets, Rhegen aims to contribute significantly to the field of therapeutics, emphasizing both market potential and clinical value.

GenAssist Therapeutics, founded in July 2020 by a team of leading scientists and industry experts, specializes in the development of gene therapy drugs utilizing advanced base editing technology. The company is focused on addressing neuromuscular diseases that currently lack effective treatments, particularly Duchenne Muscular Dystrophy (DMD) and Spinal Muscular Atrophy (SMA). GenAssist aims to provide permanent cures by precisely repairing disease-causing genes directly within patients' cells. The company holds global intellectual property rights to its proprietary Targeted AID-based Mutagenesis (TAM) technology, positioning it at the forefront of innovative solutions for a range of genetic disorders.

Biosysen operates as a synthetic biology company specializing in species design. It employs software engineering principles to enhance biological productivity through self-replicating, scalable systems. The company's core offerings include artificial species libraries and associated pipelines tailored to specific industrial needs, with a focus on food, daily chemicals, and protein drug research and development.

ProfoundBio is a clinical-stage biotechnology company focused on developing novel antibody-based therapeutics with curative potential for cancer, including antibody-drug conjugate candidates targeting solid tumors and hematologic malignancies that are in discovery, preclinical, and clinical development, with programs designed to leverage the immune system to eradicate cancer through targeted therapeutics.

Full-Life Technologies specializes in developing and commercializing radiopharmaceuticals for cancer therapy. It offers research and development, production, and distribution services within the radiotherapy sector, aiming to enhance patient outcomes through innovative nuclear medicine solutions.

Bioforany is a biocatalyst manufacturer focused on the development and sale of innovative biocatalysts for various industries. The company produces a range of products, including chiral alcohols, chiral amines, chiral hydroxy acids, amino acids, chiral epoxides, lipases, oxidoreductases, and epoxidases. Utilizing advanced green biomanufacturing technology, Bioforany offers low-carbon solutions that cater to multiple sectors, such as pharmaceutical intermediates, traditional Chinese medicine decoction components, functional food, animal nutrition, daily chemical care, plant protection, and renewable materials.

MoleculeMind is an AI-driven protein design platform focused on revolutionizing protein discovery, optimization, and design. The company utilizes advanced AI algorithms to enhance the drug development process and has applications across various sectors, including industrial production, agriculture, material design, and environmental improvement. MoleculeMind offers an integrated biological computing platform that enables the prediction and design of peptides, antibodies, enzymes, and small proteins, facilitating industrial-scale protein optimization and design for diverse research and application needs.

Jitai Medicine (METiS) is a biotechnology company that uses artificial intelligence to drive drug delivery and drug discovery. It combines advanced technologies like artificial intelligence, machine learning, and quantum simulation to achieve more effective design of innovative delivery materials, drug candidate selection and formulation design, "programmable nucleic acid drug" development, and nucleic acid delivery design.

Grit Science is a biotechnology company specializing in gene therapeutics, focusing on the research and development of liver-related genetic treatments. The firm is dedicated to creating innovative medical products that address clinical needs and enhance human health. Through its commitment to advancing biopharmaceutical technology, Grit Science aims to provide effective solutions in the field of genetic medicine.

PhaBuilder is a technology-driven company established in February 2021 by Professor Guoqiang Chen, specializing in synthetic biology with a focus on the engineering application of halophilic microbes. The company employs advanced techniques in Next Generation Industrial Biotechnology to create high-value products such as biodegradable polyhydroxyalkanoates (PHA), ectoine, and cadaverine, targeting multiple sectors, including materials and pharmaceuticals. PhaBuilder is currently constructing two PHA production facilities in China and aims to establish 3-5 large-scale production sites within five years. The company utilizes an interdisciplinary approach that combines biology, engineering, and information technology to transform genetic programs, thereby offering sustainable solutions across diverse fields. With significant backing from notable investors, PhaBuilder is dedicated to integrating synthetic biotechnology into everyday life and advancing intelligent biological manufacturing, with the overarching goal of fostering a greener future through microbial innovation.

Vibrant develops an AI drug development platform to focus on building immune system-related drug pipelines. The company will use artificial intelligence algorithms to accelerate the efficiency of drug development in various aspects such as target discovery, drug design, and drug efficacy evaluation; at the same time, the company expects to continuously improve the success rate of drug development through sustainable data accumulation and algorithm optimization. It was founded and headed by Dr. Wang Luquan and is based in Guangzhou, Guangdong, China.

Jitai Medicine (METiS) is a biotechnology company that uses artificial intelligence to drive drug delivery and drug discovery. It combines advanced technologies like artificial intelligence, machine learning, and quantum simulation to achieve more effective design of innovative delivery materials, drug candidate selection and formulation design, "programmable nucleic acid drug" development, and nucleic acid delivery design.

Shanghai Duoning Biotechnology Co., Ltd. specializes in the development of serum-free, personalized, and chemically defined cell culture media for the biopharmaceutical industry. Founded in 2005 and based in Shanghai, the company offers a range of products, including basic media, feed media, and cell therapy media. Duoning Biotech is dedicated to providing tailored media development, cell culture process optimization, and commissioned formula production services, utilizing its expertise in animal cell culture concepts. The company supports the research, development, and commercialization of biologics products by delivering comprehensive solutions that encompass technical support and customized services tailored to the needs of pharmaceutical and scientific research institutions.

Wuhan Neurophth Biotechnology Co., Ltd. is a pioneering ophthalmology gene drug research and development company based in Wuhan, China, established in 2008. It focuses on gene therapies for ocular genetic diseases, with a particular emphasis on Leber hereditary optic neuropathy (LHON), a condition caused by genetic mutations. Neurophth has made significant advancements in the field, completing the world's first clinical study of gene therapy for LHON in 2011, which involved nine patients and has since observed their progress over seven years. The company aims to develop effective treatments for various ophthalmic disorders, including degenerative optic nerve injuries and vascular retinopathy, thereby providing physicians with innovative therapeutic options for patients suffering from these conditions.

ComGen Pharma is a biotechnology company that specializes in the research and development of innovative therapeutic drugs targeting the complement system. The company aims to create effective immunotherapies for autoimmune diseases and tumors by focusing on new and key targets within this biological pathway. Recently, ComGen Pharma secured nearly 100 million yuan in financing, which will primarily support phase I clinical trials for its complement inhibitors, advance its drug pipeline, and enhance its innovative drug research and development platform. The financing round was led by prominent investors, including Sequoia China and Yahui Investment, with additional support from Fuchuang Investment and Renyou Investment.

Structure Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing oral small-molecule medicines for chronic diseases with high unmet medical needs. Its platform combines structure-based drug design, computational chemistry, and data integration to create orally available therapies that overcome limitations of biologics and peptide drugs. The company concentrates on targeting G-protein coupled receptors and other mechanisms, leveraging structural insights to identify differentiated, efficacious, and safe treatments. Its programs address cardiovascular, metabolic, and pulmonary conditions, with a focus on delivering convenient, effective medicines that can offer broad patient impact and commercial potential. Structure Therapeutics conducts its research and development activities across its pipeline within a single organization and seeks to advance clinical candidates through development.

Cellular Biomedicine Group, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative immunotherapies for cancer and stem cell therapies for degenerative diseases in Greater China. The company employs proprietary cell-based technologies, including various forms of CAR-T therapy, which targets different cancer types, and human adipose-derived mesenchymal progenitor cells aimed at treating joint diseases. Its product pipeline features therapies such as CD20 and CD22 CAR-T for B cell malignancies, and alpha fetoprotein TCR-T targeting hepatocellular carcinoma. Additionally, Cellular Biomedicine is developing knee osteoarthritis treatments, including AlloJoin and Re-Join, the latter having completed Phase IIb trials. The company also engages in broader biopharmaceutical activities, encompassing research and development, technical support, and manufacturing of pharmaceutical polypeptides and medical devices. It has established a partnership with Novartis Pharma AG to produce and supply the CAR-T cell therapy Kymriah in China. Founded in 2001, Cellular Biomedicine Group is headquartered in New York, New York, and draws on a wealth of cellular medicine research and expertise from scientists and clinicians across the United States, England, and China.

XtalPi is a pharmaceutical technology company that applies quantum mechanics, artificial intelligence, and high-performance computing to accelerate drug discovery and development. Its Intelligent Digital Drug Discovery and Development platform weaves physics-based modeling with AI to increase efficiency, accuracy, and success rates at critical stages of R&D. The company offers tools for crystal structure prediction and determination, solid-state testing and analysis, and crystallization process development, as well as solid-state screening and evaluation, enabling faster optimization of drug candidates. XtalPi also provides drug design support for small molecules and collaboration options in antibody and peptide research, and offers platform-based AI model development and integration across pharmaceutical workflows. Founded in 2014, it is based in Cambridge, Massachusetts, with additional offices in China.

Shanghai Anovent Pharmaceutical Co., Ltd., founded in 2017 and headquartered in Shanghai, China, specializes in the development of high-quality inhalation medicines tailored for hospitals and medical institutions. The company focuses on offering safe and affordable pharmaceutical products, which include both generic and specialized inhalation therapies. By providing these medications, Anovent aims to enhance the quality of medical treatment available to patients in healthcare settings.

Joyo Pharma focuses on the research and development of drugs for the treatment of tumors, autoimmunity, metabolism, and infectious diseases.

PhaBuilder is a technology-driven company established in February 2021 by Professor Guoqiang Chen, specializing in synthetic biology with a focus on the engineering application of halophilic microbes. The company employs advanced techniques in Next Generation Industrial Biotechnology to create high-value products such as biodegradable polyhydroxyalkanoates (PHA), ectoine, and cadaverine, targeting multiple sectors, including materials and pharmaceuticals. PhaBuilder is currently constructing two PHA production facilities in China and aims to establish 3-5 large-scale production sites within five years. The company utilizes an interdisciplinary approach that combines biology, engineering, and information technology to transform genetic programs, thereby offering sustainable solutions across diverse fields. With significant backing from notable investors, PhaBuilder is dedicated to integrating synthetic biotechnology into everyday life and advancing intelligent biological manufacturing, with the overarching goal of fostering a greener future through microbial innovation.

Westlake Therapeutics is a biopharmaceutical company based in Hangzhou, China, founded in 2019. The company specializes in developing innovative cell therapies aimed at treating a range of human diseases, including cancer, rare disorders, and immunological and metabolic conditions. Central to its approach is the REDx platform, which enables the engineering of red blood cells and utilizes genetic modifications of hematopoietic stem and progenitor cells sourced from peripheral blood, bone marrow, or cord blood. This technology facilitates the creation of personalized treatment solutions, enhancing the potential for effective therapies tailored to individual patient needs.

ProfoundBio is a clinical-stage biotechnology company focused on developing novel antibody-based therapeutics with curative potential for cancer, including antibody-drug conjugate candidates targeting solid tumors and hematologic malignancies that are in discovery, preclinical, and clinical development, with programs designed to leverage the immune system to eradicate cancer through targeted therapeutics.

dMed Company Limited, also known as dMed Biopharmaceutical Co., Ltd., is a clinical contract research organization based in Shanghai, China. Established in 2016, dMed specializes in offering a comprehensive range of services to support the development of medicines and medical devices. Its offerings include consulting, clinical operations, biostatistics and programming, data management, pharmacovigilance, clinical science and medical affairs, quality assurance, and regulatory affairs and strategy. The company serves a diverse clientele, including biopharmaceutical and medical device companies, and aims to establish itself as a prominent international brand in the field of drug innovation services and solutions.

neoX Biotech is a Beijing-based biotechnology company founded in 2018 that specializes in the development of antigen-based cancer vaccines. By integrating artificial intelligence with biophysics, neoX Biotech focuses on the discovery and development of macromolecular and multispecific drugs, primarily in the field of immuno-oncology. The company has established a platform for early therapeutic discovery, which includes neoantigen prediction and T cell receptor screening, as well as the characterization of protein-protein interactions. This innovative approach aims to provide effective treatments for cancer patients by advancing drug research and development.

Biosysen operates as a synthetic biology company specializing in species design. It employs software engineering principles to enhance biological productivity through self-replicating, scalable systems. The company's core offerings include artificial species libraries and associated pipelines tailored to specific industrial needs, with a focus on food, daily chemicals, and protein drug research and development.

MoonBiotech is a biotechnology company focused on the commercialization of microbial resources.

Insilico Medicine, Inc. is a biotechnology company that leverages artificial intelligence (AI) to transform drug discovery, biomarker development, and aging research. Founded in 2014 and based in Baltimore, Maryland, the company has established itself as a pioneer in applying advanced AI techniques, such as generative adversarial networks and reinforcement learning, to create novel molecular structures for various diseases, including cancer and age-related conditions. Insilico Medicine operates an integrated platform that covers all stages of drug discovery, from initial research to clinical trial analysis. Its projects include Pharma.AI, which offers machine learning services to various sectors, and Young.AI, a platform focused on aging predictors. The company also pursues internal drug discovery initiatives targeting diseases like Alzheimer's and Parkinson's, and has partnered with Life Extension to produce nutraceutical products utilizing deep learning and bioinformatics. Additionally, Insilico Medicine provides consumer applications aimed at enhancing health and longevity.

HiFiBiO is a biotherapeutics company focused on harnessing the human immune system to address diseases, particularly cancer and autoimmune disorders. Founded in 2013 and based in Paris, the company specializes in proprietary single-cell technologies that facilitate drug and biomarker discovery and development. HiFiBiO's platform combines extensive biological knowledge with advanced single-cell profiling techniques, allowing for the rapid identification and advancement of antibody drugs. Through partnerships with both industry and academic institutions, HiFiBiO aims to promote open innovation and enhance patient outcomes by unlocking the therapeutic potential of the immune system.

Stemirna Therapeutics is a RNA technology based drug development company designed to maximize the potential of RNA science. The company currently has more than a dozen of independently-developed mRNA drug projects, focusing on the fields of mRNA-based personalized cancer vaccines, mRNA vaccines for infectious disease, protein defects diseases, and genetic diseases, providing cure and solutions for cancer and infectious diseases, better serving patients.

Phanes Therapeutics is a biotechnology company specializing in drug discovery for immuno-oncology and eye diseases. Established in 2016, the company focuses on developing monoclonal antibodies for solid tumors and conditions like age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. Additionally, they work on bispecific antibodies targeting small cell lung cancer.

VivaVision Biotech is a clinical-stage R&D biopharmaceutical company that is developing novel medicines to treat topical diseases. VivaVision Biotech is dedicated to bringing new therapeutics to millions of patients suffering from chronic ocular or dermal inflammatory diseases.

OnCusp Therapeutics is a biopharmaceutical company dedicated to accelerating oncology medication innovation globally. It focuses on translating preclinical drug candidates into clinical proof-of-concept stage and advancing them for rapid global early clinical development.

Wuhan Neurophth Biotechnology Co., Ltd. is a pioneering ophthalmology gene drug research and development company based in Wuhan, China, established in 2008. It focuses on gene therapies for ocular genetic diseases, with a particular emphasis on Leber hereditary optic neuropathy (LHON), a condition caused by genetic mutations. Neurophth has made significant advancements in the field, completing the world's first clinical study of gene therapy for LHON in 2011, which involved nine patients and has since observed their progress over seven years. The company aims to develop effective treatments for various ophthalmic disorders, including degenerative optic nerve injuries and vascular retinopathy, thereby providing physicians with innovative therapeutic options for patients suffering from these conditions.

Beijing Yuanxin is a technology company that offers an integrated healthcare platform for pharmaceutical distribution and health insurance.

neoX Biotech is a Beijing-based biotechnology company founded in 2018 that specializes in the development of antigen-based cancer vaccines. By integrating artificial intelligence with biophysics, neoX Biotech focuses on the discovery and development of macromolecular and multispecific drugs, primarily in the field of immuno-oncology. The company has established a platform for early therapeutic discovery, which includes neoantigen prediction and T cell receptor screening, as well as the characterization of protein-protein interactions. This innovative approach aims to provide effective treatments for cancer patients by advancing drug research and development.

Visen Pharmaceuticals is an innovative biopharmaceutical company focused on developing and providing advanced treatments for endocrine diseases in China. With a patient-centric approach, Visen aims to deliver first-in-class or best-in-class products, covering both common and rare endocrine conditions in adults and children. The company leverages cutting-edge technologies and global resources, with established offices in Shanghai, Beijing, Hong Kong, and Taipei, along with a Greater China R&D and manufacturing site in Suzhou.

Shanhu Health is a company focused on advancing digital medicine through the development of clinical application software. It specializes in creating computerized systems that enhance clinical research processes, including interactive response technology, electronic data capture, and clinical trial management systems, all built on cloud technology. By leveraging digital intelligence, Shanhu Health accelerates drug development and offers consultancy services for risk-based monitoring and the implementation of clinical research management systems.

dMed Company Limited, also known as dMed Biopharmaceutical Co., Ltd., is a clinical contract research organization based in Shanghai, China. Established in 2016, dMed specializes in offering a comprehensive range of services to support the development of medicines and medical devices. Its offerings include consulting, clinical operations, biostatistics and programming, data management, pharmacovigilance, clinical science and medical affairs, quality assurance, and regulatory affairs and strategy. The company serves a diverse clientele, including biopharmaceutical and medical device companies, and aims to establish itself as a prominent international brand in the field of drug innovation services and solutions.

SciNeuro Pharmaceuticals is a biotechnology company based in Shanghai, China, focused on developing innovative medicines for patients with central nervous system (CNS) diseases. The company is committed to transforming the treatment landscape for these conditions through a robust product pipeline that emphasizes internal innovation and global collaboration. SciNeuro's drug development is guided by breakthrough scientific evidence, including insights from human genetics and pharmacology, targeting the underlying mechanisms of CNS diseases. By addressing these pathological mechanisms, SciNeuro aims to provide transformative therapies that not only aim to cure these diseases but also enhance the quality of life for patients.

D3 Bio, established in 2020, is a biotechnology company headquartered in China. It specializes in the development and registration of innovative medicines, primarily focusing on oncology and immunology. The company's approach involves analyzing clinical and market data to identify gaps in current treatments, employing unique drug development methodologies to target new disease areas and routes, and ultimately providing patients with alternative therapeutic options.

XtalPi is a pharmaceutical technology company that applies quantum mechanics, artificial intelligence, and high-performance computing to accelerate drug discovery and development. Its Intelligent Digital Drug Discovery and Development platform weaves physics-based modeling with AI to increase efficiency, accuracy, and success rates at critical stages of R&D. The company offers tools for crystal structure prediction and determination, solid-state testing and analysis, and crystallization process development, as well as solid-state screening and evaluation, enabling faster optimization of drug candidates. XtalPi also provides drug design support for small molecules and collaboration options in antibody and peptide research, and offers platform-based AI model development and integration across pharmaceutical workflows. Founded in 2014, it is based in Cambridge, Massachusetts, with additional offices in China.

LP Pharmaceuticals (Xiamen) Co., Ltd., located in Xiamen Biomedical Industry Base which formulates and manufactures pharmaceuticals with enhanced delivery properties. The company was founded in 2012 by a group of scientists and business professionals with extensive experience in the US and Chinese pharmaceutical industry. Proprietary delivery platforms include mucosal and oral controlled release. Therapeutic areas currently concern central nervous system, digestive system, cardiovascular, cancer and AIDS.

Dizal Pharmaceutical is a research-driven biotechnology company that specializes in the discovery, development, and commercialization of innovative medicines. The company focuses on creating first-in-class and best-in-class therapeutic solutions, emphasizing the development of groundbreaking drugs. With a commitment to advancing healthcare, Dizal engages in extensive research and development activities, alongside production and sales of its pharmaceutical products. Through its efforts, Dizal aims to contribute significantly to the pharmaceutical industry by delivering effective treatments that address unmet medical needs.

neoX Biotech is a Beijing-based biotechnology company founded in 2018 that specializes in the development of antigen-based cancer vaccines. By integrating artificial intelligence with biophysics, neoX Biotech focuses on the discovery and development of macromolecular and multispecific drugs, primarily in the field of immuno-oncology. The company has established a platform for early therapeutic discovery, which includes neoantigen prediction and T cell receptor screening, as well as the characterization of protein-protein interactions. This innovative approach aims to provide effective treatments for cancer patients by advancing drug research and development.

Simcha Therapeutics is a biopharmaceutical company focused on developing engineered cytokine immunotherapy for cancer treatment. Founded in 2018 and headquartered in New Haven, Connecticut, the company utilizes directed evolution to create novel cytokines that enhance the immune system's ability to combat diseases. Its lead program, ST-067, is a designer IL-18 cytokine that has demonstrated significant antitumor effects in animal models, both as a standalone treatment and in combination with anti-PD-1 checkpoint inhibitors. This innovative approach aims to provide patients with more effective immunotherapies, thereby improving their ability to fight cancer.

Beijing Yuanxin is a technology company that offers an integrated healthcare platform for pharmaceutical distribution and health insurance.

Wuhan Neurophth Biotechnology Co., Ltd. is a pioneering ophthalmology gene drug research and development company based in Wuhan, China, established in 2008. It focuses on gene therapies for ocular genetic diseases, with a particular emphasis on Leber hereditary optic neuropathy (LHON), a condition caused by genetic mutations. Neurophth has made significant advancements in the field, completing the world's first clinical study of gene therapy for LHON in 2011, which involved nine patients and has since observed their progress over seven years. The company aims to develop effective treatments for various ophthalmic disorders, including degenerative optic nerve injuries and vascular retinopathy, thereby providing physicians with innovative therapeutic options for patients suffering from these conditions.

Adagene is a clinical-stage biotechnology company focused on developing immuno-oncology antibodies targeting novel epitopes. It employs its proprietary Smart Antibody Technology to enhance success rates, expedite time to market, and reduce development costs for therapeutic antibodies.

Transcenta Holding is a clinical-stage biopharmaceutical company that offers fully integrated capabilities in antibody discovery, research and development, manufacturing, and business development. The company concentrates on developing innovative antibody-based therapeutics for oncology and selected non-oncology indications, including bone and kidney disorders, with a pipeline that includes Osemitamab (TST001), TST002, TST003, TST006, MSB2311, MSB0254, TST808, and other candidates. Headquartered with multiple sites in China—Suzhou, Shanghai, Hangzhou, and Beijing—and with research and development and operations in the United States at Waltham and Princeton, Transcenta operates as a global biotherapeutics business. Founded in 2019, the company aims to advance therapeutic antibodies through discovery, development, and manufacturing to address unmet patient needs. Its business scope encompasses clinical research and trial services alongside its development programs, positioning it to accelerate pipeline progress and collaborate on global opportunities.

Shanghai Anovent Pharmaceutical Co., Ltd., founded in 2017 and headquartered in Shanghai, China, specializes in the development of high-quality inhalation medicines tailored for hospitals and medical institutions. The company focuses on offering safe and affordable pharmaceutical products, which include both generic and specialized inhalation therapies. By providing these medications, Anovent aims to enhance the quality of medical treatment available to patients in healthcare settings.

HiFiBiO is a biotherapeutics company focused on harnessing the human immune system to address diseases, particularly cancer and autoimmune disorders. Founded in 2013 and based in Paris, the company specializes in proprietary single-cell technologies that facilitate drug and biomarker discovery and development. HiFiBiO's platform combines extensive biological knowledge with advanced single-cell profiling techniques, allowing for the rapid identification and advancement of antibody drugs. Through partnerships with both industry and academic institutions, HiFiBiO aims to promote open innovation and enhance patient outcomes by unlocking the therapeutic potential of the immune system.

Yaoyanshe, established in 2012 and headquartered in Shanghai, China, operates as a Contract Research Organization (CRO) technology platform. It specializes in providing end-to-end services for pharmaceutical research and development, including clinical monitoring, project management, registration affairs, biostatistics, pharmacovigilance, medical affairs, and Site Management Organization (SMO) services. The company's core offering is an application designed to facilitate value sharing and trading within the industry, empowering patients with up-to-date treatment information and enabling professionals to assess creditworthiness, analyze competition, and evaluate sponsor projects more effectively. Yaoyanshe aims to address key industry challenges and enhance the efficiency of pharmaceutical research and development.

Tencent Trusted Doctors, a company established in early August 2018 upon the merger of Tencent Doctorwork and Trusted Doctors, is acquiring the start-up in an attempt to create a private healthcare network that provides both online and offline services through the so-called "celebrity effect".

Cullgen Inc. is a clinical-stage biopharmaceutical company developing small molecule therapeutics based on its uSMITE platform, which enables targeted protein degradation by using novel E3 ligands to selectively degrade disease-causing proteins. The approach aims to address cancers, inflammatory and autoimmune diseases, and other conditions lacking effective therapies. Founded in 2018 and based in San Diego, Cullgen's pipeline includes degrader programs such as TRK and GSPT1, as well as other candidates like DAC.

Beijing Yuanxin is a technology company that offers an integrated healthcare platform for pharmaceutical distribution and health insurance.

BrightGene Bio-Medical Technology Company is a biopharmaceutical firm based in Suzhou, China, specializing in the research, development, manufacturing, and commercialization of innovative medicines and high-quality generic active pharmaceutical ingredients (APIs) and finished dosage forms (FDFs). The company has a diverse product pipeline that includes immuno-oncological agents, GLP-1 receptor agonists for type 2 diabetes, and antibody-drug conjugates aimed at treating solid tumors and brain cancers. Additionally, BrightGene develops a variety of treatments such as Eribulin, Trabectedin, and various macromolecules and cytotoxic payloads. Its product offerings span multiple therapeutic areas, including oncology, cardiology, infectious diseases, and immunology. Founded in 2001, BrightGene has positioned itself as a leader in small molecules and nucleotide drugs, focusing on advancing therapeutics across all stages of development.

Transcenta Holding is a clinical-stage biopharmaceutical company that offers fully integrated capabilities in antibody discovery, research and development, manufacturing, and business development. The company concentrates on developing innovative antibody-based therapeutics for oncology and selected non-oncology indications, including bone and kidney disorders, with a pipeline that includes Osemitamab (TST001), TST002, TST003, TST006, MSB2311, MSB0254, TST808, and other candidates. Headquartered with multiple sites in China—Suzhou, Shanghai, Hangzhou, and Beijing—and with research and development and operations in the United States at Waltham and Princeton, Transcenta operates as a global biotherapeutics business. Founded in 2019, the company aims to advance therapeutic antibodies through discovery, development, and manufacturing to address unmet patient needs. Its business scope encompasses clinical research and trial services alongside its development programs, positioning it to accelerate pipeline progress and collaborate on global opportunities.

Xiaoyaoyao is a comprehensive pharmaceutical circulation field in the era of big data and the Internet As a service provider. Xiaoyaoyao's "Pharmaceutical Help" platform is an e-commerce platform that has been approved by the State Food and Drug Administration and has a B2B drug wholesale license, integrating drug procurement, warehousing, sales, logistics and distribution. , subverting the traditional procurement model of hierarchical distribution. At present, the business has covered more than 20 provinces across the country, with a storage area of ​​nearly 500,000 square meters, serving more than 3,000 suppliers and more than 500,000 pharmacies and clinic end customers across the country.

Beijing Deep Intelligent Pharma Technology Co., Ltd. specializes in leveraging artificial intelligence and blockchain technology to enhance drug discovery, development, and medical affairs for pharmaceutical companies. Founded in 2017 and based in Beijing, the company offers a range of products, including a multi-language medical machine translation engine, intelligent pharmacovigilance for risk management, and tools for creating multilingual educational materials. Deep Intelligent Pharma also provides AI-enabled solutions for medical writing, document review, and quality control, as well as a patient search ecosystem to facilitate medical and clinical research. Additionally, the company offers intelligent regulatory affairs solutions to streamline drug research and development processes. Operating globally, including in China, the United States, and Japan, Deep Intelligent Pharma aims to improve the efficiency and quality of the pharmaceutical development lifecycle.

Farcast Biosciences, established in 2019, is a clinical diagnostic company based in Boston, Massachusetts, with operations in Bangalore, India. The company specializes in developing and utilizing a proprietary Human Tumor Micro Dynamics (HTMD) platform. This platform preserves the natural state of human tumors through the culture of fresh, unmodified tumor fragments, creating a human tumor microenvironment. Farcast's technology enables oncologists to evaluate individual tumors and predict patient response to treatments before initiating therapy. Additionally, it serves drug developers and researchers by providing accurate and precise models for testing and analysis, facilitating the development of personalized cancer therapies.

Eden Biologics is a biopharmaceutical company that focuses on developing biosimilars and providing contract development and manufacturing services to clients and partners in the biopharmaceutical industry. The company specializes in producing complex dosage forms, including oral solids, liquids, semi-solids for both prescription and over-the-counter products, as well as macromolecule biologics. Eden Biologics offers expertise in manufacturing biologics from cell line development through commercial production, with a global and regional regulatory affairs knowledge base to ensure affordability and accessibility of biopharmaceuticals worldwide.

Founded in 2018, Brii Biosciences is a biotechnology company dedicated to researching, developing, and commercializing medicines for chronic illnesses, with a primary focus on infectious diseases. Headquartered in Durham, North Carolina, the company operates additional offices in Shanghai and Beijing, China; and San Francisco, California.

GRAIL focuses on developing technologies for early cancer detection. Founded in 2016, the company specializes in a pan-cancer screening test that measures circulating nucleic acids in blood using high-intensity sequencing.

HiFiBiO is a biotherapeutics company focused on harnessing the human immune system to address diseases, particularly cancer and autoimmune disorders. Founded in 2013 and based in Paris, the company specializes in proprietary single-cell technologies that facilitate drug and biomarker discovery and development. HiFiBiO's platform combines extensive biological knowledge with advanced single-cell profiling techniques, allowing for the rapid identification and advancement of antibody drugs. Through partnerships with both industry and academic institutions, HiFiBiO aims to promote open innovation and enhance patient outcomes by unlocking the therapeutic potential of the immune system.

CStone Pharmaceuticals, founded in 2015, focuses on developing and commercializing innovative immunotherapy and precision treatment drugs for cancer patients worldwide. Its pipeline comprises over a dozen candidates targeting various indications, with immuno-oncology at its core.

Adagene is a clinical-stage biotechnology company focused on developing immuno-oncology antibodies targeting novel epitopes. It employs its proprietary Smart Antibody Technology to enhance success rates, expedite time to market, and reduce development costs for therapeutic antibodies.

Moderna is a biotechnology company focused on messenger RNA therapeutics and vaccines. It develops mRNA-based medicines that instruct cells to produce therapeutic proteins or antibodies in vivo, targeting infectious diseases, oncology, cardiovascular diseases, and rare genetic disorders. Founded in 2010 and headquartered in Cambridge, Massachusetts, the company has built a broad pipeline with multiple development candidates across several modalities and a track record highlighted by a COVID-19 vaccine authorized in the United States. Moderna collaborates with major pharmaceutical and research partners, including AstraZeneca, Merck, Vertex, and Alexion, as well as academic institutions such as Harvard University and Karolinska Institutet. It maintains manufacturing collaborations with Lonza for mRNA production and Catalent for fill-finish, and engages with public sector and philanthropic supporters such as BARDA, DARPA, and the Gates Foundation. As of 2025, the company continued expanding its mRNA development program across infectious disease, oncology, cardiovascular, and rare genetic diseases.

XtalPi is a pharmaceutical technology company that applies quantum mechanics, artificial intelligence, and high-performance computing to accelerate drug discovery and development. Its Intelligent Digital Drug Discovery and Development platform weaves physics-based modeling with AI to increase efficiency, accuracy, and success rates at critical stages of R&D. The company offers tools for crystal structure prediction and determination, solid-state testing and analysis, and crystallization process development, as well as solid-state screening and evaluation, enabling faster optimization of drug candidates. XtalPi also provides drug design support for small molecules and collaboration options in antibody and peptide research, and offers platform-based AI model development and integration across pharmaceutical workflows. Founded in 2014, it is based in Cambridge, Massachusetts, with additional offices in China.

Farcast Biosciences, established in 2019, is a clinical diagnostic company based in Boston, Massachusetts, with operations in Bangalore, India. The company specializes in developing and utilizing a proprietary Human Tumor Micro Dynamics (HTMD) platform. This platform preserves the natural state of human tumors through the culture of fresh, unmodified tumor fragments, creating a human tumor microenvironment. Farcast's technology enables oncologists to evaluate individual tumors and predict patient response to treatments before initiating therapy. Additionally, it serves drug developers and researchers by providing accurate and precise models for testing and analysis, facilitating the development of personalized cancer therapies.

Health 724 is a health service provider based on users, health managers, and health products. They offer direct supply of health products to users who are concerned about their own and their families' health, as well as customized health solutions.

Shanghai MOLBASE Technology Co., Ltd. is a prominent player in the chemical e-commerce sector, offering a comprehensive platform that connects buyers and vendors of chemicals. Founded in 2011 and headquartered in Shanghai, the company provides a robust compound database and e-commerce solutions tailored for the pharmaceutical, biotech, specialty industries, and research organizations. MOLBASE enables professional buyers to inquire about and purchase a wide range of chemicals through a centralized website that features real-time product data updates. The platform leverages artificial intelligence technologies to enhance its services, which include business intelligence, financing information, and logistics facilitation. Recognized as the largest chemical e-commerce platform in China by gross merchandise value in 2017 and 2018, MOLBASE continues to serve as an integrated resource for chemical transactions and related services globally.

Zai Lab is a biopharmaceutical company dedicated to discovering and developing transformative medicines for cancer, autoimmune, and infectious diseases. Founded in Shanghai in 2014, the company focuses on bringing innovative therapies to patients worldwide. Zai Lab's pipeline includes proprietary drug candidates such as Niraparib, Optune, Ripretinib, and Margetuximab, among others. The company collaborates with global biopharma leaders to expand its pipeline and foster innovation in China.

Founded in 2015, Orasis Pharmaceuticals specializes in developing corrective eye drops for treating presbyopia. Its lead product, CSF-1, improves near visual acuity by pupil modulation, eliminating the need for reading glasses.

Baheal Pharmaceutical Group is a pharmaceutical commercialization platform that specializes in providing comprehensive marketing services for pharmaceutical product manufacturers. The company offers a range of services, including health brand marketing promotion, wholesale distribution of pharmaceuticals, and retail services. By focusing on these key areas, Baheal aims to enhance the market presence of its clients and facilitate the distribution of pharmaceutical products.

Founded in 2001, Celon Laboratories is a Hyderabad-based pharmaceutical company specializing in the development, manufacturing, and marketing of niche therapy products. Its portfolio includes oncology and critical care products, available in various dosage forms, serving markets across Asia Pacific, Africa, Latin America, CIS countries, and Eastern Europe.

Akumentis Healthcare Ltd, founded in 2010 and based in Thane, India, is a prominent manufacturer of pharmaceutical products specializing in branded generics. The company holds a strong market position in various therapeutic areas, particularly in women's health, and offers a diverse range of healthcare solutions aimed at addressing challenging medical conditions. Its product portfolio includes treatments for anti-infections, infertility, gynecology, musculo-skeletal issues, gastroenterology, orthopedics, and dermatology, among others. As a subsidiary of Akums Drugs and Pharmaceuticals Ltd, Akumentis Healthcare is dedicated to delivering effective healthcare products that cater to specific needs in the market.

Tencent Trusted Doctors, a company established in early August 2018 upon the merger of Tencent Doctorwork and Trusted Doctors, is acquiring the start-up in an attempt to create a private healthcare network that provides both online and offline services through the so-called "celebrity effect".

La Renon is a healthcare company dedicated to providing high-quality pharmaceutical products and services aimed at addressing critical illnesses and chronic diseases. Founded by a team of experienced professionals from various sectors of the healthcare industry, the company focuses on treating a wide range of conditions, including nephrology, neurological disorders, critical care, gynecology, orthopedics, gastroenterology, urology, respiratory issues, and cardio-metabolic diseases. La Renon emphasizes continuous value addition to its business model, striving to create a unique platform that benefits all stakeholders involved. The company aims to enhance the capabilities of healthcare professionals, ultimately improving patient outcomes and quality of life.

Zai Lab is a biopharmaceutical company dedicated to discovering and developing transformative medicines for cancer, autoimmune, and infectious diseases. Founded in Shanghai in 2014, the company focuses on bringing innovative therapies to patients worldwide. Zai Lab's pipeline includes proprietary drug candidates such as Niraparib, Optune, Ripretinib, and Margetuximab, among others. The company collaborates with global biopharma leaders to expand its pipeline and foster innovation in China.

Curatio Healthcare Pvt. Ltd. is a specialty dermatology company focused on addressing therapy gaps in both general and specialty dermatology. The company develops a range of dermatology and cosmetology products, including those for skincare, baby care, and hair care. Its offerings encompass targeted solutions for pigmentary disorders, emollients, protectives, and acne therapy. By leveraging extensive market research, Curatio identifies the needs of dermatologists and cosmetologists, transforming innovative ideas into effective products. The company's world-class research and development expertise, combined with collaboration with research partners, enables it to deliver high-quality solutions tailored to the daily challenges faced by professionals in the field.

Zai Lab is a biopharmaceutical company dedicated to discovering and developing transformative medicines for cancer, autoimmune, and infectious diseases. Founded in Shanghai in 2014, the company focuses on bringing innovative therapies to patients worldwide. Zai Lab's pipeline includes proprietary drug candidates such as Niraparib, Optune, Ripretinib, and Margetuximab, among others. The company collaborates with global biopharma leaders to expand its pipeline and foster innovation in China.

Tencent Trusted Doctors, a company established in early August 2018 upon the merger of Tencent Doctorwork and Trusted Doctors, is acquiring the start-up in an attempt to create a private healthcare network that provides both online and offline services through the so-called "celebrity effect".

Zhangshang Yaodian is a pharmacy app that provides safe medication services.

Paras Pharmaceuticals Limited is a prominent player in the fast-moving consumer goods sector in India, specializing in the development and manufacture of healthcare and personal care products. The company offers a diverse range of items, including skin and hair care products, deodorants, prickly heat powders, absorbent dusting powders, and pain-relieving ointments. Additionally, it provides solutions for cracked heels, itch relief, ringworm, and cold and cough symptoms, along with analgesic pills, hand sanitizers, skin defense talc, and contraceptive pills. Serving both domestic and international markets, Paras Pharmaceuticals focuses on retailing, marketing, and distributing well-known household brands within the healthcare and personal care categories.

Betta Pharmaceuticals, established in 2003, is a leading Chinese pharmaceutical company specializing in the research, development, manufacturing, and marketing of innovative medicines. Its primary focus is on treating severe diseases like malignant tumors, diabetes, and cardio-cerebrovascular diseases. Betta's flagship product, Icotinib Hydrochloride (Conmana), is a pioneering targeted anti-cancer drug developed in China, used for treating non-small-cell lung cancer. The company has a strong pipeline with over 20 new drug development projects and holds more than 100 authorized patents. Betta Pharmaceuticals is headquartered in Hangzhou, with additional facilities in Beijing, and employs nearly 1,000 people, including many returned PhD holders. It has successfully listed on the GEM of the Shenzhen Stock Exchange and has received numerous awards for its innovative work, including the First Prize of National Prize for Progress in Science and Technology.

Nenter is a company based in China that specializes in the production, development, and sale of pharmaceutical intermediates and chiral chemicals. The firm's product offerings include a range of medical intermediates, as well as finished dosage forms such as tablets and capsules. Additionally, Nenter produces vitamin E supplements, contributing to its diverse product portfolio in the healthcare sector. Through its focus on high-quality chemical production, Nenter plays a significant role in the pharmaceutical supply chain.

Founded in 2001, Celon Laboratories is a Hyderabad-based pharmaceutical company specializing in the development, manufacturing, and marketing of niche therapy products. Its portfolio includes oncology and critical care products, available in various dosage forms, serving markets across Asia Pacific, Africa, Latin America, CIS countries, and Eastern Europe.

Eddingpharm, established in 2001, is a pharmaceutical company focused on supplying high-quality patented and branded drugs to the Chinese healthcare market. The company aims to bridge the gap between Chinese patients and global medicines by acquiring classic branded medications from multinational corporations and introducing innovative patented drugs. Eddingpharm has rapidly expanded its operations across China, deploying nearly 1,000 professional representatives in 30 provinces, with access to over 19,000 hospitals and 20,000 pharmacies. Its collaborations with multinational pharmaceutical companies and leading research institutions have enriched its product portfolio, particularly in therapy areas such as oncology, cardiovascular, respiratory, and renal diseases. A notable product in its line is Vascepa®, a prescription medication that lowers triglyceride levels without raising LDL cholesterol. Eddingpharm has been granted development and commercialization rights for Vascepa® in mainland China, Hong Kong, Macau, and Taiwan, and is currently conducting clinical trials to support its regulatory registrations. The company's commitment to professionalism, excellence, responsibility, and persistence underpins its mission to enhance treatment options for patients in China.

China Nuokang Bio-Pharmaceutical Inc. is a fully integrated, profitable bio-pharmaceutical company focused on researching, developing, manufacturing and marketing hematological and cardiovascular products. They sell a portfolio of fourteen products, which includes principal products Baquting®, a flagship hemocoagulase, and Aiduo®, a cardiovascular stress imaging agent. There product pipeline includes product candidates under development in hematological, cardiovascular and cerebrovascular disease diagnosis, treatment and prevention.

Excel PharmaStudies Inc. (依格斯医疗科技有限公司) is a company focused on clinical research and contract research. It maintains close contact with government departments, industries, hospitals, and research institutes. PharmaStudies has conducted 123 clinical research projects from I to IV period in about 130 hospitals of 40 cities with the invovlment of 25,000 patients. It was founded in 1999, and is one of the earliest clinical research & contract research organizations in China.

SAI Life Sciences is a global pharmaceutical services provider offering integrated solutions across drug discovery, development, and manufacturing for clients worldwide. Established in 1999, the company specializes in discovering, developing, and manufacturing medicines, with a focus on small molecule new chemical entities (NCEs). SAI operates through multiple facilities in India, Japan, the United States, and Europe, offering services such as synthetic chemistry, medicinal chemistry, biology, pharmacology, toxicology, and late-phase manufacturing. Its mission is to enable partners to develop innovative medicines more efficiently by providing reliable, high-quality scientific solutions.

ReaMetrix, Inc., established in 2003, is a biotechnology service provider headquartered in San Carlos, California, with an additional office in Bangalore, India. The company specializes in offering research and development services, including GMP-level assay development, validation, and testing to pharmaceutical, biotechnology, and diagnostic industries across the United States, India, and Japan. ReaMetrix provides labeled reagents and reagent kits for cell biology platforms, along with custom labeling and conjugation services tailored to clients' specifications.